Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

347 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Immune responses against shared antigens are common in esophago-gastric cancer and can be enhanced using CD40-activated B cells.
Thelen M, Keller D, Lehmann J, Wennhold K, Weitz H, Bauer E, Gathof B, Brüggemann M, Kotrova M, Quaas A, Mallmann C, Chon SH, Hillmer AM, Bruns C, von Bergwelt-Baildon M, Garcia-Marquez MA, Schlößer HA. Thelen M, et al. J Immunother Cancer. 2022 Dec;10(12):e005200. doi: 10.1136/jitc-2022-005200. J Immunother Cancer. 2022. PMID: 36600602 Free PMC article.
Bispecific antibodies redirect synthetic agonistic receptor modified T cells against melanoma.
Märkl F, Benmebarek MR, Keyl J, Cadilha BL, Geiger M, Karches C, Obeck H, Schwerdtfeger M, Michaelides S, Briukhovetska D, Stock S, Jobst J, Müller PJ, Majed L, Seifert M, Klüver AK, Lorenzini T, Grünmeier R, Thomas M, Gottschlich A, Klaus R, Marr C, von Bergwelt-Baildon M, Rothenfusser S, Levesque MP, Heppt MV, Endres S, Klein C, Kobold S. Märkl F, et al. J Immunother Cancer. 2023 May;11(5):e006436. doi: 10.1136/jitc-2022-006436. J Immunother Cancer. 2023. PMID: 37208128 Free PMC article.
Modification of Lugano criteria by pre-infusion tumor kinetics improves early survival prediction for patients with lymphoma under chimeric antigen receptor T-cell therapy.
Winkelmann M, Blumenberg V, Rejeski K, Quell C, Bücklein V, Ingenerf M, Unterrainer M, Schmidt C, Dekorsy FJ, Bartenstein P, Ricke J, von Bergwelt-Baildon M, Subklewe M, Kunz WG. Winkelmann M, et al. J Immunother Cancer. 2023 Oct;11(10):e006659. doi: 10.1136/jitc-2022-006659. J Immunother Cancer. 2023. PMID: 37880181 Free PMC article.
TIGIT+ NK cells in combination with specific gut microbiota features predict response to checkpoint inhibitor therapy in melanoma patients.
Tsakmaklis A, Farowski F, Zenner R, Lesker TR, Strowig T, Schlößer H, Lehmann J, von Bergwelt-Baildon M, Mauch C, Schlaak M, Knuever J, Schweinsberg V, Heinzerling LM, Vehreschild MJGT. Tsakmaklis A, et al. Among authors: von bergwelt baildon m. BMC Cancer. 2023 Nov 28;23(1):1160. doi: 10.1186/s12885-023-11551-5. BMC Cancer. 2023. PMID: 38017389 Free PMC article.
Combined targeting of soluble latent TGF-ß and a solid tumor-associated antigen with adapter CAR T cells.
Werchau N, Kotter B, Criado-Moronati E, Gosselink A, Cordes N, Lock D, Lennartz S, Kolbe C, Winter N, Teppert K, Engert F, Webster B, Mittelstaet J, Schaefer D, Mallmann P, Mallmann MR, Ratiu D, Assenmacher M, Schaser T, von Bergwelt-Baildon M, Abramowski P, Kaiser AD. Werchau N, et al. Oncoimmunology. 2022 Nov 11;11(1):2140534. doi: 10.1080/2162402X.2022.2140534. eCollection 2022. Oncoimmunology. 2022. PMID: 36387056 Free PMC article.
Potent high-avidity neutralizing antibodies and T cell responses after COVID-19 vaccination in individuals with B cell lymphoma and multiple myeloma.
Keppler-Hafkemeyer A, Greil C, Wratil PR, Shoumariyeh K, Stern M, Hafkemeyer A, Ashok D, Hollaus A, Lupoli G, Priller A, Bischof ML, Ihorst G, Engelhardt M, Marks R, Finke J, Bertrand H, Dächert C, Muenchhoff M, Badell I, Emmerich F, Halder H, Spaeth PM, Knolle PA, Protzer U, von Bergwelt-Baildon M, Duyster J, Hartmann TN, Moosmann A, Keppler OT. Keppler-Hafkemeyer A, et al. Nat Cancer. 2023 Jan;4(1):81-95. doi: 10.1038/s43018-022-00502-x. Epub 2022 Dec 21. Nat Cancer. 2023. PMID: 36543907 Free PMC article.
Comparative performance of scFv-based anti-BCMA CAR formats for improved T cell therapy in multiple myeloma.
Stock S, Fertig L, Gottschlich A, Dörr J, Märkl F, Majed L, Menkhoff VD, Grünmeier R, Rejeski K, Cordas Dos Santos DM, Theurich S, von Bergwelt-Baildon M, Endres S, Subklewe M, Kobold S. Stock S, et al. Among authors: von bergwelt baildon m. Cancer Immunol Immunother. 2024 Apr 17;73(6):100. doi: 10.1007/s00262-024-03688-4. Cancer Immunol Immunother. 2024. PMID: 38630291 Free PMC article.
347 results